Hydrogel-Based Intranasal Delivery Systems for The Treatment of Allergic Rhinitis

Allergic rhinitis, as the most common type of rhinitis, has become a global health problem. At present, oral/intranasal administration of H-1-antihistamines and corticosteroids is considered to be the main therapeutic method for allergic rhinitis. However, the local bioavailability of the drug is low due to the systemic effect of drugs and nasal mucociliary clearance. More recently, a hydrogel-based intranasal delivery system (HIDS) is proposed and gradually developed as an emerging strategy for allergic rhinitis treatment by extending the residence time of drugs in a controlled manner. This review aims to highlight the advances in HIDS for allergic rhinitis treatment. The designs and therapeutic effect of the existing HIDS in the nasal microenvironment are described in detail. This review also provides a perspective on the future opportunities and developments of HIDS. Despite its nascent status, the future clinical and translational applications of HIDS can have a transformative impact on improving the treatment of chronic inflammation in the nasal cavity.

Automated summary

Allergic rhinitis is a global health problem, and oral/intranasal administration of H-1-antihistamines and corticosteroids is the main therapeutic method. However, the low local bioavailability of drugs hinders effective treatment. Recently, a hydrogel-based intranasal delivery system (HIDS) has emerged as a promising strategy to extend drug residence time. This review discusses the designs, therapeutic effects, and future prospects of HIDS for allergic rhinitis treatment.